- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00565474
Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant
February 21, 2017 updated by: Novartis Pharmaceuticals
A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled, 6-month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients
Principal objective is to investigate if the treatment with fluvastatin can prevent the progression of vascular graft disease in de novo renal transplant patients.
Study Overview
Study Type
Interventional
Enrollment (Actual)
84
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patients where the investigator expects to prescribe cyclosporine, mycophenolate mofetil and corticosteroids as base immunosuppressive therapy, regardless of their participation in the study.
- Man or woman aged from 17 to 70 years.
- Patients that receive a first or second renal transplant from a non-living donor
- Patients where allograft biopsies may be performed.
- Patients receiving an identical or compatible ABO graft.
- Patients willing to give their written informed consent to all study issues.
- Women with child-bearing potential should use a medically proven contraceptive method during the study.
- Patients able to meet all study requirements.
Exclusion criteria:
- Patients with pre-transplant cholesterol levels above 240 mg/dl (6.2 mmol/l).
- Positive cross-match of T cells or ABO incompatibility with the donor.
- Recipients of multiorgan transplant.
- Patients with diabetes mellitus.
- HIV seropositive or with surface antigen of Hepatitis B .
- Kidney from a donor aged over 65 years.
- Last panel of reactive antibody (PRA) above 50%.
- Women who plan to get pregnant within 12 months, or who are pregnant and/or nursing.
- Patients with a history of cancer in the previous 5 years, except for patients successfully treated with localized carcinoma of squamous or basal cells of the skin, or cervix cancer in situ treated adequately.
- Patients receiving an investigational drug in the 30 days prior to the transplant and/or who will receive an investigational/non-registered drug during the study, except for the use of erythropoietin-stimulating products
- Patients with myocardial infarction within the 6 months prior to the transplant, uncontrollable cardiac arrhythmia or another severe or unstable medical condition probably affecting the safety of the patient or the study objectives.
- Patients with alcohol dependence or drug abuse not solved, or signs of organic lesion caused by alcohol, mental dysfunction or other factors limiting their ability to fully cooperate with the study.
- Patients where it is planned to perform an induction treatment with preparations containing antilymphocyte antibodies (ALG, ATG or OKT-3).
- Patients scheduled to receive cyclosporine i.v. for over 48 hours.
- Patients with liver dysfunction (ALT or AST values or total bilirubin 2 times above the upper limit of the normal ranges of the laboratory values).
- Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
fluvastatin 40mg b.i.d.
|
Graft vasculopathy
|
Placebo Comparator: 2
Placebo b.i.d.
|
Graft vasculopathy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if treatment with fluvastatin can prevent the progression of vascular graft disease. The difference between the vascular intimal thickness measured on the baseline biopsy and the biopsy at the end of the study between the two treatment group
Time Frame: three Yrs
|
three Yrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
24-hour creatinine and proteinuria values at 6 months post-transplant, graft survival and patient survival at 6 months, differences in lipid profile between the treatment groups, incidence of rejection episodes treated and documented by biopsy at 6
Time Frame: Three yrs
|
Three yrs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2001
Primary Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
November 28, 2007
First Submitted That Met QC Criteria
November 29, 2007
First Posted (Estimate)
November 30, 2007
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 21, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LESTX-ES-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft Vasculopathy
-
University of AarhusNovo Nordisk A/SEnrolling by invitationCardiac Allograft Vasculopathy | Acute Cellular Graft Rejection | Mitochondrial Function | Primary Graft FailureDenmark
-
Novartis PharmaceuticalsCompletedGraft RejectionUnited States
-
Sahlgrenska University Hospital, SwedenUnknownCardiac Allograft Vasculopathy | Graft Dysfunction | Chronic Rejection of Cardiac TransplantSweden
-
Lee S NguyenCompletedHeart Failure | Cardiac Death | Cardiac Allograft Vasculopathy | Acute Cellular Graft Rejection | Cardiac Transplant Disorder | Immune Tolerance | Heart Transplant Rejection | Antibody-Mediated Graft Rejection
-
Peking Union Medical College HospitalBayerRecruitingPolypoidal Choroidal VasculopathyChina
-
Universita di VeronaCompletedCardiac Allograft VasculopathyItaly, Netherlands
-
Federico II UniversityCompleted
-
University of MinnesotaWithdrawnCardiac Allograft VasculopathyUnited States
-
Sun Yat-sen UniversityCompletedPolypoidal Choroidal VasculopathyChina
-
University of MinnesotaWithdrawnCardiac Allograft VasculopathyUnited States
Clinical Trials on Fluvastatin
-
Bader, Ted, M.D.US Department of Veterans AffairsCompleted
-
NovartisCompleted
-
AORTICA GroupTerminated
-
NovartisCompletedHypercholesterolemia | Mixed DyslipidemiaChina
-
NovartisCompletedMetabolic SyndromeGermany
-
NovartisCompletedMixed Dyslipidemia | Heterozygous Familial HypercholesterolemiaSwitzerland
-
Novartis PharmaceuticalsCompleted
-
University of ZurichUniversity of BaselCompletedInsulin Resistance | Clinical Trial | Adipose Tissue, BrownSwitzerland
-
University of BolognaUnknown
-
NovartisCompletedMetabolic SyndromeTurkey